Obesity may increase the prevalence of Parkinson’s Disease (PD) while PD may reduce obesity index in patients
Main Article Content
Abstract
Objective: Currently, Parkinson’s disease (PD) is becoming more common among younger people of ages from 30 – 40 years. The incidence is higher among patients with higher body mass index (BMI), and some reports had it that Obesity is a risk factor for PD while some reported that there is no relationship between obesity and PD. PD patient at the time of diagnosis has an above-normal BMI but which goes below normal as the disease progresses. Therefore, it is essential to explore the relationship between PD and Obesity.
Methods: 349 outpatients and inpatients with PD were selected from Jiangsu University Affiliated People’s Hospital from January 2014 to December 2018, while 74 inpatients with non-cerebrovascular illness in the same period were selected as the control group. According to Hoehn-Yahr grade, Parkinson’s patients were divided into three groups. The height, weight, waist and hip circumference, total cholesterol (TC), Total Glycerol (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) were measured and recorded. The relationship between the severity of Parkinson’s disease and blood lipids was evaluated.
Results: The BMI of patients with PD in the early stage was higher than that of the control group, but lower than that of the control group in the late stage, and the level of blood lipid in the patients with early PD was significantly higher than that in the control group and patients with advanced PD, especially in TG. The waist circumference and hip circumference of the patients with early PD were higher than those in the control group, but there was no statistical difference.
Conclusion: i) Obesity may increase the prevalence of PD. ii) The BMI of patients with PD shows two-way changes in different periods. iii) The BMI is higher and cholesterol is more elevated in the early stage of patients with PD, while at the advanced stage of the disease, the BMI and lipid levels of the patients showed a downward trend, which may be associated with a metabolic syndrome associated with dopamine depletion.
Article Details
Copyright (c) 2020 Zhong LX, et al.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Ray CK, Healy DG, Schapira AHV. Non-motor symptoms of Parkinson's disease: Diagnosis and management. The lancet Neurology. 2006; 5: 235-245.
Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, et al. Obesity, Diabetes and Risk of Parkinson Disease Mov Disord. 2011; 26: 2253-2259. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21739472
Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. The lancet Neurology. 2004; 3: 169-178.
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006; 14: 840-846.
Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes care. 2007; 30: 842-847. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17251276
Chen J, Guan Z, Wang L, Song G, Ma B, et al. Meta-Analysis: Overweight, Obesity, and Parkinson's Disease. Int J Endocrinol. 2014; 2014: 203930. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24672544
Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio Al. Obesity and the Risk of Parkinson's Disease. Am J Epidemiol. 2004; 159: 547-555. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15003958
Whitmer RA, Gunderson EP, Barrett-Connor E, Quesenberry CP Jr, Yaffe K. Obesity in middle age and future risk of dementia: a 27-year longitudinal population-based study. BMJ. 2005; 11: 1360. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15863436
Hendricks EJ. Off-label drugs for weight management. Diabetes, Metabolic Syndrome. Obesity. 2017; 10: 223-234.
Jagjit S, Rajiv K. Phentermine-topiramate: First combination drug for obesity. Int J Appl Basic Med Res. 2015; 5: 157-158.
Ryder JR, Kaizer A, Rudser KD, Gross A, Kelly AS, et al. Effect of phentermine on weight reduction in a pediatric weight management. Int J Obes. 2017; 41: 90-93. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27773937
Meguid MM, Fetissov SO, Madhu V, Sato T, Zhang L, et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition. 2000; 16: 843-857.
Schwartz MW1, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000; 404: 661-671. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10766253
William JL, Lysia SF. The hypothalamus in parkinson disease. Annals of Neurology. 1978; 3: 97-186.
Shannak KRA, Rozdilsky B, Kish S, Gilbert J, Hornykiewicz O. Noradrenaline, dopamine and serotonin levels and metabolism in the human hypothalamus: observations in Parkinson's disease and normal subjects. Brain Res. 1994; 639: 33-41. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/8180836
Lill CM. Genetics of Parkinson's disease: Molecular Cellular Probes. 2016; 30: 386-396.
Anna D, Wassilios GM. Environmental risk factors and genetics of Parkinson's disease, Presse Med. 2017; 46: 175-181. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28189372
Andrew BS, Matthew JF, Vincenzo B. The genetics of Parkinson's disease: progress and therapeutic implication. Mov Disord. 2013; 28: 14-23.
Pei Z, Bo. Metabolic Syndrome: An Important Risk Factor for Parkinson's Disease. Oxid Med Cell Longev. 2014; 2014: 729194. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24955210
Abbott RD, Ross GW, White LR, Nelson JS, Masaki KH, et al. Midlife adiposity and the future risk of Parkinson's disease. Neurology. 2002; 59: 1051-1057. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/12370461
Lee EB, Mattson MP. The neuropathology of obesity: insights from human disease. Acta Neuropathol. 2014; 127: 3-28. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24096619
Hu G, Jousilahti P, Nissinen A, Antikainen R, Kivipelto M, et al. Body mass index and the risk of Parkinson diseases. Neurology. 2006; 67: 1955-1959.
Chen CM. Overview of obesity in Mainland China. Obes Rev. 2008; 9: 14-21. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18307694
Morales BH, Cervantes AA, Rodríguez VM, Calleja CJ, Corona T. Overweight is more prevalent in patients with Parkinson's disease. Arq Neuropsiquiatr. 2012; 70: 843-846. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23175195
Walker RW, Howells AR, Gray WK. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease. Parkinsonism Relat Disord. 2011; 17: 27-29. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21051272
Nam GE, Kim SM, Han K, Kim NH, Chung HS, et al. Metabolic syndrome and risk of Parkinson disease: A nationwide cohort study. PLoS Med. 2018; 1371: 1002640. PubMed: https://www.ncbi.nlm.nih.gov/pubmed/30130376